Madrid, Spain.Langley RG, Gooderham M, Papp KA, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Articles by Madrid, Spain.Langley RG, Gooderham M, Papp KA, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5